RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
RIGEL PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $333.93M | $325.16M | $309.96M | $291.70M | $262.40M | $231.69M | $209.92M | $185.55M | $167.81M | $152.29M | $147.06M | $137.74M | 120.6% | +27.3% |
| Product sales, net | $251.42M | $243.36M | $231.98M | $213.09M | $187.95M | $162.45M | $144.90M | $127.92M | $116.12M | $106.55M | $104.29M | $97.54M | 90.8% | +33.8% |
| Contract revenues from collaborations and other | $25.10M | $56.15M | $62.03M | $68.99M | $79.97M | $40.63M | $34.38M | $29.46M | $14.08M | $12.69M | $11.49M | $31.83M | 9.1% | -68.6% |
| Delivery of drug supplies, royalties and others | $21.10M | $16.17M | $19.05M | $22.01M | $22.99M | $23.63M | $20.38M | $19.46M | $14.01M | $12.62M | $11.41M | $6.37M | 7.6% | -8.2% |
| Development Milestones | $4.00M | $0 | $3.00M | – | – | – | – | – | – | – | $75.00K | – | 1.4% | – |
| Government contracts | – | – | – | – | – | – | – | – | – | – | $1.10M | – | – | – |
| License revenue | – | – | – | – | – | – | $14.00M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Rigel Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.